Skip to main content
. 2019 Jan 28;4(5):656–666. doi: 10.1016/j.ekir.2019.01.014

Table 3.

Adverse events during the first year of transplantation, n (%)

Days of hospitalization, mean ± SD 49 ± 45
 Range, d 8–357
BK virus 16 (10.3)
CMV 67 (42.9)
Infection 134 (83.2)
 Severe infection 96 (60)
 Bacterial infection 112 (69.6)
 Recurrent urinary tract infections 29 (18.7)
 Pneumonitis 31 (19.6)
 Viral infection 21 (13.3)
 Fungal infection 16 (10.1)
 Parasitic infection 6 (3.9)
Cardiovascular event 73 (45.1)
 ADHF 23 (13.5)
 Recurrent ADHF 10 (5.8)
 Deep vein thrombosis/Pulmonary embolism 22 (12.9)
 Arrhythmia 19 (11.1)
 Myocardial ischemia 10 (5.8)
 Cerebrovascular event 3 (1.8)
Urologic complication 94 (56.9)
 Lymphocele 19 (11.1)
 Hematoma 19 (11.1)
 Acute urinary retention 18 (10.5)
 Ureteral stenosis 18 (10.5)
 Transplant renal artery stenosis 9 (5.3)
Skin tumor 11 (7.1)
Solid tumor 5 (3.2)
Hemopathy/Lymphoma 6 (3.8)
TCMR 27 (17.1)
 Time to TCMR, d (mean ± SD) 124 ± 104
ABMR 8 (5.2)
 Time to ABMR, d (mean ± SD) 171 ± 128
Death 17 (9.9)
Cause of death
 Infection 10 (58.8)
 Cardiovascular disease 5 (29.4)
Graft loss 40 (23.4)
Death-censored graft loss 29 (16.9)
Cause of graft loss
 Death 11 (28.2)
 Rejection 10 (25.6)
 Vascular 7 (17.9)

ABMR, antibody-mediated rejection; ADHF, acute decompensated heart failure; CMV, cytomegalovirus; TCMR, T-cell mediated rejection.